Yirui Sun

Washington University in St. Louis
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Unlike CG methylation alone, which is associated with stable and moderate levels of transcription, gene body methylation in both CG and CHG contexts is associated with poorly transcribed and missanotated genes. Recent results show that removal of this TE-like methylation from a set of maize pollen specific genes promotes high-level transcription. Here we report that TE-like methylated genes that are maternally demethylated are expressed toward the extreme high end of the spectrum in endosperm. As with their pollen counterparts, they have few exons, and are enriched for short, secreted proteins. Nearly half encode zeins, the major seed storage proteins of maize. When methylation is high in promoters as well as in gene bodies, their paternal copies are silenced in endosperm, resulting in genomic imprinting. These findings reveal that sporophytic TE-like methylation in gene bodies can be a signature of nearly-constitutive silencing but high and specific expression in endosperm or pollen.

Year:

2025

In metastatic breast cancer, HER2 -activating mutations frequently co-occur with mutations in PIK3CA , TP53 , or CDH1 . Of these co-occurring mutations, HER2 and PIK3CA are the most commonly comutated gene pair, with approximately 40% of HER2 -mutated breast cancers also having activating mutations in PIK3CA . To study the effects of co-occurring HER2 and PIK3CA mutations, we generated genetically engineered mice with the HER2 V777L ; PIK3CA H1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids. HP breast cancers showed accelerated tumor formation in vivo and increased invasion and migration in in vitro assays. HP breast cancer cells were resistant to the pan-HER tyrosine kinase inhibitor, neratinib, but were effectively treated with neratinib plus the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan. Proteomic and RNA-seq analysis of HP breast cancers identified increased gene expression of cyclin D1 and p21WAF1/Cip1 and changes in cell-cycle markers. Combining neratinib with CDK4/6 inhibitors was another effective strategy for treating HP breast cancers, with neratinib plus palbociclib showing a statistically significant reduction in development of mouse HP tumors as compared to either drug alone. The efficacy of both the neratinib plus trastuzumab deruxtecan and neratinib plus palbociclib combinations was validated using a human breast cancer patient-derived xenograft with very similar HER2 and PIK3CA mutations to the HP mice. Further, these two drug combinations effectively treated spontaneous lung metastasis in syngeneic mice transplanted with HP breast cancer organoids. This study provides valuable preclinical data to support the ongoing phase 1 clinical trials of these drug combinations in breast cancer. Significance: In HER2 -mutated breast cancer, PIK3CA mutation activates p21–CDK4/6–cyclin D1 signaling to drive resistance to HER2-targeted therapies, which can be overcome using CDK4/6 inhibitors.

Year:

2025

In metastatic breast cancer, HER2 activating mutations frequently co-occur with mutations in the PIK3CA, TP53, or E-cadherin genes. Of these co-occurring mutations, HER2 and PIK3CA mutations are the most prevalent gene pair, with approximately 40% of HER2 mutated breast cancers also having activating mutations in PIK3CA. To study the effects of co-occurring HER2 and PIK3CA mutations, we bred genetically engineered mice with the HER2V777L; PIK3CAH1047R transgenes (HP mice) and studied the resulting breast cancers both in vivo as well as ex vivo using cancer organoids. HP breast cancers show accelerated tumor formation in vivo and increased invasion and migration in in vitro assays. HP breast cancers have resistance to the pan-HER tyrosine kinase inhibitor, neratinib, but are effectively treated by neratinib plus trastuzumab deruxtecan. Proteomic and RNA-Seq analysis of HP breast cancers showed increased gene expression of Cyclin D1 and p21WAF1/Cip1 and changes in cell cycle markers. Combining neratinib with CDK4/6 inhibitors was another effective strategy for HP breast cancers with neratinib plus palbociclib showing a statistically significant reduction in mouse HP tumors as compared to either drug alone. We validated both the neratinib plus trastuzumab deruxtecan and neratinib plus palbociclib combinations using a human breast cancer patient-derived xenograft with very similar HER2 and PIK3CA mutations. Further, these two drug combinations effectively treated spontaneous lung metastasis in syngeneic mice transplanted with HP breast cancer organoids. Both of these drug combinations are being tested in phase 1 clinical trials and this study provides valuable preclinical evidence for them.

Year:

2024

Year:

2023

Collaborators (6)

Ron Bose

Washington University School of Medicine

UNITED STATES
View details

Jonathan Gent

Senior research associate

University of Georgia

UNITED STATES
View details

R. Kelly Dawe

University of Georgia

UNITED STATES
View details

Ian Hagemann

Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Samuel Achilefu

Chair/Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Shunqiang Li

Associate Professor

Washington University in St. Louis

UNITED STATES
View details